Skip to main content
Premium Trial:

Request an Annual Quote

Are Lion Bioscience and Genomics Solutions Broke? If You Read They Are

NEW YORK, May 29 - Some readers of's financial pages may have left the site scratching their heads recently.


The corporate "Profile" portion of the widely used search engine posted extravagantly incorrect cash balances for at least two publicly traded genomics companies. According to, Lion Bioscience and Genomic Solutions have total-cash balances of $0. In other words, they're broke.


While both companies have seen better financial days, rumors of the death of their cash balances have been greatly exaggerated. In fact, Genomic Solutions had $7.2 million in cash and cash equivalents as of March 31 and Lion managed to hold on to $112 million in cash and marketable securities.


A spokeswoman for Genomic Solutions learned of the gaffe from a reporter this afternoon. It was too late to contact Lion's headquarters in Heidelberg, Germany. Officials from Yahoo! or, whose data uses in some of its spreadsheets, did not return telephone calls seeking comment.


To be fair, a different part of "Financials" link rather than "Profile"--links to a page called "Balance Sheet," which lists correct asset valuations.

It was not immediately known how long the erroneous data have been posted. And it will be difficult at best to determine whether the information had an effect on either company's stock performance.


Rubberneckers can go to, find "Media," link to "Finance" beside it, and enter a company's ticker symbol--Genomics Solutions' is GNSL and Lion's is LEON.


The word "Profile" will be seen in a small text box in the center of the screen. Clicking it will bring readers to the full company profile page, which includes recent events, ownership details, a financial summary, executive compensation, and, at the very end, a section called "Statistics at a Glance." In the third column is the category "Financial Strength," which lists the firm's debt-to-equity ratio and total cash.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.